Sagespring Wealth Partners LLC Has $360,000 Stock Holdings in Insulet Corporation $PODD

Sagespring Wealth Partners LLC increased its position in shares of Insulet Corporation (NASDAQ:PODD) by 12.0% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,147 shares of the medical instruments supplier’s stock after purchasing an additional 123 shares during the quarter. Sagespring Wealth Partners LLC’s holdings in Insulet were worth $360,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the company. Inspire Investing LLC increased its holdings in shares of Insulet by 299.5% during the first quarter. Inspire Investing LLC now owns 4,119 shares of the medical instruments supplier’s stock worth $1,082,000 after buying an additional 3,088 shares in the last quarter. Gradient Investments LLC acquired a new stake in Insulet during the 2nd quarter valued at $17,429,000. Goldman Sachs Group Inc. raised its position in Insulet by 1.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 579,302 shares of the medical instruments supplier’s stock valued at $152,130,000 after purchasing an additional 10,628 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its stake in Insulet by 55.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 5,229 shares of the medical instruments supplier’s stock worth $1,376,000 after purchasing an additional 1,867 shares in the last quarter. Finally, Vident Advisory LLC bought a new stake in shares of Insulet during the first quarter worth $216,000.

Analysts Set New Price Targets

A number of research analysts recently issued reports on PODD shares. Canaccord Genuity Group lifted their price target on Insulet from $353.00 to $399.00 and gave the company a “buy” rating in a report on Monday, September 29th. Citigroup reaffirmed a “buy” rating on shares of Insulet in a report on Tuesday, July 8th. Morgan Stanley reissued an “overweight” rating on shares of Insulet in a research note on Thursday, August 7th. Zacks Research raised Insulet from a “hold” rating to a “strong-buy” rating in a research note on Tuesday. Finally, Rothschild & Co Redburn lifted their price objective on Insulet from $350.00 to $370.00 and gave the stock a “buy” rating in a research report on Friday, October 3rd. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Insulet presently has a consensus rating of “Moderate Buy” and a consensus target price of $348.05.

Insider Transactions at Insulet

In other Insulet news, SVP Laetitia Cousin sold 797 shares of the company’s stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the sale, the senior vice president owned 3,890 shares of the company’s stock, valued at approximately $1,356,870.90. This represents a 17.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Prem Singh sold 687 shares of the stock in a transaction on Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the sale, the senior vice president owned 3,456 shares in the company, valued at approximately $1,200,925.44. This trade represents a 16.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.39% of the company’s stock.

Insulet Stock Performance

Shares of Insulet stock opened at $318.59 on Friday. The firm has a fifty day moving average of $326.22 and a two-hundred day moving average of $301.98. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. The stock has a market capitalization of $22.43 billion, a price-to-earnings ratio of 96.84, a PEG ratio of 2.64 and a beta of 1.40. Insulet Corporation has a 52 week low of $226.50 and a 52 week high of $353.50.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, topping analysts’ consensus estimates of $0.92 by $0.25. The business had revenue of $649.10 million during the quarter, compared to analysts’ expectations of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The firm’s quarterly revenue was up 32.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, equities research analysts predict that Insulet Corporation will post 3.92 EPS for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.